+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08376(GK Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08376(GK Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

GK antibodies, a class of immunoglobulins, have gained attention in biomedical research due to their unique binding properties and potential therapeutic applications. Initially identified in studies targeting autoimmune disorders, these antibodies are characterized by their specificity for glycolipid or glycoprotein epitopes, particularly those involving glucose kinase (GK)-related structures. Their discovery emerged from investigations into immune responses in metabolic diseases, where aberrant glycan modifications on cell surfaces were linked to pathogenic mechanisms.

Structurally, GK antibodies often exhibit high-affinity binding domains shaped by somatic hypermutation, enabling precise recognition of conserved carbohydrate motifs. This feature has spurred interest in leveraging them for diagnostics, such as detecting disease-specific glycan biomarkers in cancers or neurodegenerative conditions. Additionally, their ability to modulate cellular signaling pathways—by blocking pathogenic protein-carbohydrate interactions—has positioned them as candidates for immunotherapy development.

Recent research explores engineering GK antibodies to enhance stability and reduce immunogenicity, with some progressing to preclinical trials for autoimmune and infectious diseases. Challenges remain in understanding their cross-reactivity and optimizing production methods. Nonetheless, their dual role as research tools and therapeutic agents underscores their growing relevance in precision medicine and glycobiology.